Kamada Ltd. (NASDAQ:KMDA) has earned an average rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $9.00.
KMDA has been the subject of several recent research reports. Zacks Investment Research downgraded Kamada from a “buy” rating to a “hold” rating in a report on Wednesday, July 25th. HC Wainwright set a $11.00 target price on shares of Kamada and gave the stock a “buy” rating in a report on Wednesday, August 8th. ValuEngine upgraded shares of Kamada from a “strong sell” rating to a “sell” rating in a report on Monday, July 16th. Finally, BidaskClub upgraded shares of Kamada from a “hold” rating to a “buy” rating in a report on Thursday, September 27th.
KMDA stock opened at $5.40 on Friday. The company has a quick ratio of 2.85, a current ratio of 3.95 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $217.42 million, a P/E ratio of 30.00 and a beta of 1.34. Kamada has a 1-year low of $4.26 and a 1-year high of $6.45.
Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $33.84 million during the quarter, compared to the consensus estimate of $29.64 million. Kamada had a return on equity of 14.43% and a net margin of 11.79%. On average, sell-side analysts anticipate that Kamada will post 0.21 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC raised its holdings in Kamada by 101.7% in the third quarter. Acadian Asset Management LLC now owns 590,431 shares of the biotechnology company’s stock worth $3,647,000 after purchasing an additional 297,636 shares in the last quarter. Jane Street Group LLC bought a new position in Kamada in the second quarter worth about $146,000. Macquarie Group Ltd. raised its holdings in Kamada by 71.7% in the second quarter. Macquarie Group Ltd. now owns 47,547 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 19,851 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Kamada by 8.1% in the second quarter. Renaissance Technologies LLC now owns 464,900 shares of the biotechnology company’s stock worth $2,417,000 after purchasing an additional 34,800 shares in the last quarter. Finally, ARK Investment Management LLC raised its holdings in Kamada by 14.8% in the second quarter. ARK Investment Management LLC now owns 119,537 shares of the biotechnology company’s stock worth $616,000 after purchasing an additional 15,440 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).
See Also: What is the yield curve?
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.